We are thrilled to announce that the first patient has been enrolled in MOTHER, a clinical trial in hepatocellular carcinoma.

Professor Julien Edeline at Centre Eugène Marquis of Rennes leads this trial. It will evaluate the safety and efficacy of EXL01, our groundbreaking live biotherapeutic designed to activate NOD2, a critical immune receptor, driving targeted metabolic reprogramming in immune cells. By administering EXL01 in combination with immune checkpoint inhibitors (i.e., immunotherapies), our goal is to boost their efficacy and convert previously non-responsive patients into responders.

This marks the third ongoing clinical trial evaluating EXL01 as an adjuvant to immunotherapy in oncology — a remarkable milestone in itself!

Keep an eye out on our page for more updates!